Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Defining EGFR amplification status for clinical trial inclusion.

French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Weller M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, van den Bent M.

Neuro Oncol. 2019 May 24. pii: noz096. doi: 10.1093/neuonc/noz096. [Epub ahead of print]

PMID:
31125418
2.

The Interview for Decisional Abilities (IDA): a tool to assess the decisional capacity of abused and neglected older adults.

Abrams RC, Ansell P, Breckman R, Karlawish J, Lachs M, Holt-Knight D, Needell N, Rogers G, LoFaso V.

J Elder Abuse Negl. 2019 Mar;31(3):244-254. doi: 10.1080/08946566.2019.1573392. Epub 2019 Feb 27.

PMID:
30810485
3.

Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.

Lassman AB, Roberts-Rapp L, Sokolova I, Song M, Pestova E, Kular R, Mullen C, Zha Z, Lu X, Gomez E, Bhathena A, Maag D, Kumthekar P, Gan HK, Scott AM, Guseva M, Holen KD, Ansell PJ, van den Bent MJ.

Clin Cancer Res. 2019 Jun 1;25(11):3259-3265. doi: 10.1158/1078-0432.CCR-18-3034. Epub 2019 Feb 22.

PMID:
30796037
4.

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.

Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.

PMID:
30686551
5.

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R.

Neuro Oncol. 2019 Jan 1;21(1):106-114. doi: 10.1093/neuonc/noy091.

6.

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.

Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D.

Br J Cancer. 2018 Apr;118(8):1042-1050. doi: 10.1038/s41416-018-0020-2. Epub 2018 Mar 19.

7.

Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, Fischer JS, Chu KL, Ames WW, Mittapalli RK, Lee HJ, Zeng J, Roberts-Rapp LA, Loberg LI, Ansell PJ, Reilly EB, Ocampo CJ, Holen KD, Tolcher AW.

Cancer. 2018 May 15;124(10):2174-2183. doi: 10.1002/cncr.31304. Epub 2018 Mar 13.

8.

Identifying perinatal depression with case-finding instruments: a mixed-methods study (BaBY PaNDA – Born and Bred in Yorkshire PeriNatal Depression Diagnostic Accuracy).

Littlewood E, Ali S, Dyson L, Keding A, Ansell P, Bailey D, Bates D, Baxter C, Beresford-Dent J, Clarke A, Gascoyne S, Gray C, Hackney L, Hewitt C, Hutchinson D, Jefferson L, Mann R, Marshall D, McMillan D, North A, Nutbrown S, Peckham E, Pervin J, Richardson Z, Swan K, Taylor H, Waterhouse B, Wills L, Woodhouse R, Gilbody S.

Southampton (UK): NIHR Journals Library; 2018 Feb. No abstract available.

PMID:
29481018
Free Books & Documents
9.

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML.

Invest New Drugs. 2018 Oct;36(5):828-835. doi: 10.1007/s10637-017-0551-z. Epub 2018 Jan 8.

10.

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.

Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, Gomez EJ, Fischer J, Mandich H, Xiong H, Lee HJ, Munasinghe WP, Roberts-Rapp LA, Ansell PJ, Holen KD, Kumthekar P.

Neuro Oncol. 2018 May 18;20(6):838-847. doi: 10.1093/neuonc/nox202.

11.

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

12.

Addressing sexual health in geriatrics education.

Brennan-Ing M, Seidel L, Ansell P, Raik BL, Greenberg D, Nicastri C, Breznay J, Karpiak SE, Adelman RD.

Gerontol Geriatr Educ. 2018 Apr-Jun;39(2):249-263. doi: 10.1080/02701960.2017.1340885. Epub 2017 Jul 18.

PMID:
28614012
13.

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.

Reck M, Blais N, Juhasz E, Gorbunova V, Jones CM, Urban L, Orlov S, Barlesi F, Kio E, Keilholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Mittapalli RK, Dunbar M, Ansell P, He L, McKee M, Giranda V, Ramalingam SS.

J Thorac Oncol. 2017 Jul;12(7):1098-1108. doi: 10.1016/j.jtho.2017.04.010. Epub 2017 Apr 29.

14.

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, Fichtel L, Sulman EP, Gomez E, Fischer J, Lee HJ, Munasinghe W, Xiong H, Mandich H, Roberts-Rapp L, Ansell P, Holen KD, Gan HK.

Neuro Oncol. 2017 Jul 1;19(7):965-975. doi: 10.1093/neuonc/now257.

15.

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.

Ramalingam SS, Blais N, Mazieres J, Reck M, Jones CM, Juhasz E, Urban L, Orlov S, Barlesi F, Kio E, Keiholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Ansell P, McKee M, Giranda V, Gorbunova V.

Clin Cancer Res. 2017 Apr 15;23(8):1937-1944. doi: 10.1158/1078-0432.CCR-15-3069. Epub 2016 Oct 10.

16.

The health care and life sciences community profile for dataset descriptions.

Dumontier M, Gray AJG, Marshall MS, Alexiev V, Ansell P, Bader G, Baran J, Bolleman JT, Callahan A, Cruz-Toledo J, Gaudet P, Gombocz EA, Gonzalez-Beltran AN, Groth P, Haendel M, Ito M, Jupp S, Juty N, Katayama T, Kobayashi N, Krishnaswami K, Laibe C, Le Novère N, Lin S, Malone J, Miller M, Mungall CJ, Rietveld L, Wimalaratne SM, Yamaguchi A.

PeerJ. 2016 Aug 16;4:e2331. doi: 10.7717/peerj.2331. eCollection 2016.

17.

Identification of depression in women during pregnancy and the early postnatal period using the Whooley questions and the Edinburgh Postnatal Depression Scale: protocol for the Born and Bred in Yorkshire: PeriNatal Depression Diagnostic Accuracy (BaBY PaNDA) study.

Littlewood E, Ali S, Ansell P, Dyson L, Gascoyne S, Hewitt C, Keding A, Mann R, McMillan D, Morgan D, Swan K, Waterhouse B, Gilbody S; BaBY PaNDA study team.

BMJ Open. 2016 Jun 13;6(6):e011223. doi: 10.1136/bmjopen-2016-011223.

18.

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.

Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya KS, Oleksijew A, Boghaert E, Song M, Sokolova I, Pestova E, Anderson M, Pappano WN, Ansell P, Bhathena A, Naumovski L, Corvaia N, Reilly EB.

BMC Cancer. 2016 Feb 16;16:105. doi: 10.1186/s12885-016-2138-z.

19.

Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.

McKeegan EM, Ansell PJ, Davis G, Chan S, Chandran RK, Gawel SH, Dowell BL, Bhathena A, Chakravartty A, McKee MD, Ricker JL, Carlson DM, Ramalingam SS, Devanarayan V.

Lung Cancer. 2015 Nov;90(2):296-301. doi: 10.1016/j.lungcan.2015.09.011. Epub 2015 Sep 15.

PMID:
26424209
20.

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.

Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ.

Invest New Drugs. 2015 Aug;33(4):870-80. doi: 10.1007/s10637-015-0242-6. Epub 2015 May 2.

21.

A phase 1 study of ABT-806 in subjects with advanced solid tumors.

Cleary JM, Reardon DA, Azad N, Gandhi L, Shapiro GI, Chaves J, Pedersen M, Ansell P, Ames W, Xiong H, Munasinghe W, Dudley M, Reilly EB, Holen K, Humerickhouse R.

Invest New Drugs. 2015 Jun;33(3):671-8. doi: 10.1007/s10637-015-0234-6. Epub 2015 Apr 17.

PMID:
25895099
22.

Prescription drug use during pregnancy and risk of childhood cancer - is there an association?

Bonaventure A, Simpson J, Ansell P, Roman E, Lightfoot T.

Cancer Epidemiol. 2015 Feb;39(1):73-8. doi: 10.1016/j.canep.2014.10.008. Epub 2014 Dec 17.

PMID:
25544150
23.

Palliative care among heart failure patients in primary care: a comparison to cancer patients using English family practice data.

Gadoud A, Kane E, Macleod U, Ansell P, Oliver S, Johnson M.

PLoS One. 2014 Nov 25;9(11):e113188. doi: 10.1371/journal.pone.0113188. eCollection 2014.

24.

The ChEMBL database as linked open data.

Willighagen EL, Waagmeester A, Spjuth O, Ansell P, Williams AJ, Tkachenko V, Hastings J, Chen B, Wild DJ.

J Cheminform. 2013 May 8;5(1):23. doi: 10.1186/1758-2946-5-23.

25.

Infectious illness in children subsequently diagnosed with acute lymphoblastic leukemia: modeling the trends from birth to diagnosis.

Crouch S, Lightfoot T, Simpson J, Smith A, Ansell P, Roman E.

Am J Epidemiol. 2012 Sep 1;176(5):402-8. doi: 10.1093/aje/kws180. Epub 2012 Aug 16.

PMID:
22899827
26.

Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.

Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP.

Cancer. 2013 Jan 15;119(2):380-7. doi: 10.1002/cncr.27758. Epub 2012 Jul 25.

27.

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.

Asahina H, Tamura Y, Nokihara H, Yamamoto N, Seki Y, Shibata T, Goto Y, Tanioka M, Yamada Y, Coates A, Chiu YL, Li X, Pradhan R, Ansell PJ, McKeegan EM, McKee MD, Carlson DM, Tamura T.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1477-86. doi: 10.1007/s00280-012-1846-6. Epub 2012 Mar 2.

28.

Survival from childhood acute lymphoblastic leukaemia: the impact of social inequality in the United Kingdom.

Lightfoot TJ, Johnston WT, Simpson J, Smith AG, Ansell P, Crouch S, Roman E, Kinsey SE.

Eur J Cancer. 2012 Jan;48(2):263-9. doi: 10.1016/j.ejca.2011.10.007.

PMID:
22206862
29.

Building psychosocial programming in geriatrics fellowships: a consortium model.

Adelman RD, Ansell P, Breckman R, Snow CE, Ehrlich AR, Greene MG, Greenberg DF, Raik BL, Raymond JJ, Clabby JF, Fields SD, Breznay JB.

Gerontol Geriatr Educ. 2011;32(4):309-20. doi: 10.1080/02701960.2011.611558.

PMID:
22087778
30.

The continuing challenge of diagnosing autism spectrum disorder in children with Down syndrome.

Gray L, Ansell P, Baird G, Parr JR.

Child Care Health Dev. 2011 Jul;37(4):459-61. doi: 10.1111/j.1365-2214.2011.01218.x. Epub 2011 Mar 23. No abstract available.

PMID:
21426369
31.

Early life exposure to diagnostic radiation and ultrasound scans and risk of childhood cancer: case-control study.

Rajaraman P, Simpson J, Neta G, Berrington de Gonzalez A, Ansell P, Linet MS, Ron E, Roman E.

BMJ. 2011 Feb 10;342:d472. doi: 10.1136/bmj.d472.

32.

Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer.

Rudin CM, Mauer A, Smakal M, Juergens R, Spelda S, Wertheim M, Coates A, McKeegan E, Ansell P, Zhou X, Qian J, Pradhan R, Dowell B, Krivoshik A, Gordon G.

J Clin Oncol. 2011 Mar 10;29(8):1075-82. doi: 10.1200/JCO.2010.32.5944. Epub 2011 Feb 7.

33.

Non-Hodgkin lymphoma and autoimmunity: does gender matter?

Ansell P, Simpson J, Lightfoot T, Smith A, Kane E, Howell D, Newton R, McGonagle D, Jack A, Roman E.

Int J Cancer. 2011 Jul 15;129(2):460-6. doi: 10.1002/ijc.25680. Epub 2010 Nov 12.

34.

Illness patterns prior to diagnosis of lymphoma: analysis of UK medical records.

Crouch S, Simpson J, Ansell P, Kane E, Howell D, Smith A, Newton R, Jack A, Roman E.

Cancer Epidemiol. 2011 Apr;35(2):145-50. doi: 10.1016/j.canep.2010.08.003. Epub 2010 Sep 15.

PMID:
20832384
35.

Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case-control study.

Mildon KH, Ansell P, Roman E, Kane EV.

Cancer Causes Control. 2010 Dec;21(12):2079-83. doi: 10.1007/s10552-010-9626-2. Epub 2010 Aug 10.

PMID:
20697798
36.

Ankle injuries in football academies: a three-centre prospective study.

Cloke DJ, Ansell P, Avery P, Deehan D.

Br J Sports Med. 2011 Jul;45(9):702-8. doi: 10.1136/bjsm.2009.067900. Epub 2010 May 29.

PMID:
20511620
37.

Oral disease in children with Down syndrome: causes and prevention.

Shore S, Lightfoot T, Ansell P.

Community Pract. 2010 Feb;83(2):18-21.

PMID:
20222361
38.

Recombinant kringle 5 from plasminogen antagonises hepatocyte growth factor-mediated signalling.

Ansell PJ, Zhang H, Davidson DJ, Harlan JE, Xue J, Brodjian S, Lesniewski R, McKeegan E.

Eur J Cancer. 2010 Mar;46(5):966-73. doi: 10.1016/j.ejca.2009.12.026. Epub 2010 Jan 12.

PMID:
20061137
39.

Brain tumor signs and symptoms: analysis of primary health care records from the UKCCS.

Ansell P, Johnston T, Simpson J, Crouch S, Roman E, Picton S.

Pediatrics. 2010 Jan;125(1):112-9. doi: 10.1542/peds.2009-0254. Epub 2009 Dec 21.

PMID:
20026498
40.

Regret-regression for optimal dynamic treatment regimes.

Henderson R, Ansell P, Alshibani D.

Biometrics. 2010 Dec;66(4):1192-201. doi: 10.1111/j.1541-0420.2009.01368.x.

PMID:
20002404
41.

Infectious proxies and childhood leukaemia: findings from the United Kingdom Childhood Cancer Study (UKCCS).

Roman E, Simpson J, Ansell P, Lightfoot T, Smith A.

Blood Cells Mol Dis. 2009 Mar-Apr;42(2):126-8. doi: 10.1016/j.bcmd.2008.10.007. Epub 2008 Dec 16. Review.

PMID:
19091606
42.

Eczema, birth order, and infection.

Hughes AM, Crouch S, Lightfoot T, Ansell P, Simpson J, Roman E.

Am J Epidemiol. 2008 May 15;167(10):1182-7. doi: 10.1093/aje/kwn042. Epub 2008 Mar 15.

PMID:
18344510
43.

Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells.

Sakla MS, Shenouda NS, Ansell PJ, Macdonald RS, Lubahn DB.

Endocrine. 2007 Aug;32(1):69-78. Epub 2007 Oct 2.

PMID:
17992604
44.

Hodgkin's lymphoma and infection: findings from a UK case-control study.

Newton R, Crouch S, Ansell P, Simpson J, Willett EV, Smith A, Burton C, Jack A, Roman E.

Br J Cancer. 2007 Nov 5;97(9):1310-4. Epub 2007 Sep 25.

45.

What determines referral of UK patients with haematological malignancies to palliative care services? An exploratory study using hospital records.

Ansell P, Howell D, Garry A, Kite S, Munro J, Roman E, Howard M.

Palliat Med. 2007 Sep;21(6):487-92.

PMID:
17846088
46.

Childhood leukaemia and infectious exposure: a report from the United Kingdom Childhood Cancer Study (UKCCS).

Simpson J, Smith A, Ansell P, Roman E.

Eur J Cancer. 2007 Nov;43(16):2396-403. Epub 2007 Sep 7.

PMID:
17826085
47.

Activation of p53 by MEG3 non-coding RNA.

Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, Ansell PJ, Zhao J, Weng C, Klibanski A.

J Biol Chem. 2007 Aug 24;282(34):24731-42. Epub 2007 Jun 13.

48.

Regulation of growth hormone expression by Delta-like protein 1 (Dlk1).

Ansell PJ, Zhou Y, Schjeide BM, Kerner A, Zhao J, Zhang X, Klibanski A.

Mol Cell Endocrinol. 2007 Jun 15;271(1-2):55-63. Epub 2007 Apr 6.

49.

Allergy and risk of childhood leukaemia: results from the UKCCS.

Hughes AM, Lightfoot T, Simpson J, Ansell P, McKinney PA, Kinsey SE, Mitchell CD, Eden TO, Greaves M, Roman E; United Kingdom Childhood Cancer Study Investigators.

Int J Cancer. 2007 Aug 15;121(4):819-24.

50.

Investigation of the sources of residential power frequency magnetic field exposure in the UK Childhood Cancer Study.

Maslanyj MP, Mee TJ, Renew DC, Simpson J, Ansell P, Allen SG, Roman E.

J Radiol Prot. 2007 Mar;27(1):41-58. Epub 2007 Mar 6. Erratum in: J Radiol Prot. 2007 Jun;27(2):207.

PMID:
17341803

Supplemental Content

Loading ...
Support Center